Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Arizona Tribune - Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Amendment to Clinical Protocol for HG-CT-1 to Include Pediatric Patients with R/R AML

Text size:

LONDON, UNITED KINGDOM / ACCESS Newswire / May 14, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has filed an amendment to the clinical protocol for its ongoing Phase I clinical trial of HG-CT-1 to include pediatric patients with relapsed/refractory acute myeloid leukemia ("R/R AML"). HG-CT-1 is the Company's CAR-T therapy, currently undergoing clinical trials in adults for the treatment of R/R AML.

This amendment, filed with the U.S. Food and Drug Administration (FDA), seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting. The expansion reflects the Company's commitment to broadening the potential impact of HG-CT-1 and addressing a critical unmet medical need in pediatric oncology.

The amendment builds on the Company's progress to date in the adult cohort of the trial, in which the first two patients have already been treated.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"We are pleased to take this important step toward making HG-CT-1 available to pediatric patients who currently have very few therapeutic options. The inclusion of children and adolescents in the trial not only reflects our commitment to addressing urgent medical needs across age groups but also supports the broader potential of HG-CT-1 as a transformative therapy for AML."

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[email protected]
Peter Redmond, Director	[email protected]
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

E.Hall--AT

GSK	-1.92%	51.09	$
RBGPF	0%	61.3	$
BTI	1.06%	61.39	$
CMSD	0.27%	22.02	$
BCE	0.69%	23.2	$
RELX	-0.19%	31.15	$
CMSC	-0.2%	22.065	$
NGG	1.52%	82.83	$
RIO	-1.65%	94.03	$
RYCEF	-0.89%	18	$
BP	-3.88%	37.86	$
BCC	7.55%	77.66	$
JRI	-0.48%	12.57	$
AZN	1.09%	183.02	$
VOD	-1.74%	13.81	$

Arizona Tribune - Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol

Featured

'Everything collapsed': Venezuela region hit hardest by quakes cries for help

Venezuela twin quakes kill at least 164, topple buildings

Venezuela twin quakes kill at least 32, injure hundreds

Kenya police in massive show of force on protest anniversary